Latest Fy26 Outlook News

DXN Limited reported a robust Q4 FY25 with 51% revenue growth, securing key contracts and completing a strategic property acquisition that strengthens its modular data centre footprint.

Boss Energy has released its FY26 guidance for the Honeymoon Uranium Operation, targeting 1.6 million pounds of uranium production and forecasting positive cash flow for the year. However, challenges in mineralisation continuity at East Kalkaroo may increase sustaining capital costs and impact future production.

Korvest Ltd has reported a record financial year with revenue up 16.2%, driven by major infrastructure projects, and declared a special dividend alongside plans for a significant Kilburn site upgrade.

MOVE Logistics Group has achieved its FY25 financial targets, showcasing significant improvements in earnings and operational efficiency despite a tough economic backdrop in New Zealand.

Microba Life Sciences reports strong Q4 FY25 growth driven by record microbiome test sales and clinician adoption in Australia and the UK, while advancing its therapeutics pipeline and targeting regional break-even in FY26.

Regis Resources closed FY25 with gold production near the top of guidance and a robust cash and bullion position of $517 million. The company’s FY26 outlook maintains steady production while ramping up growth investments amid ongoing legal and exploration developments.

Collins Foods Limited has confirmed its FY25 earnings aligned closely with market forecasts, addressing ASX concerns over potential surprises. The company highlighted positive margin outcomes and clarified the impact of a Netherlands impairment.

SunRice reported a slight decline in FY25 revenue to $1.85 billion but achieved improved profitability, driven by strategic acquisitions and operational efficiencies. The company is investing in sustainability and capacity upgrades as it pursues its 2030 Growth Strategy.

SunRice Group reported a 4% rise in net profit for FY25 alongside an 8% dividend increase, navigating inflation and currency volatility with strategic growth initiatives.

COSOL Limited anticipates solid revenue and earnings growth for FY25 despite some contract timing setbacks, with a promising outlook for FY26 driven by data analytics and managed services expansion.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

Aroa Biosurgery has reported a robust 23% revenue increase in FY25, achieving profitability and positive cash flow, setting the stage for continued growth in FY26.